Improved predictions of antibiotic efficacy can inform the development of new antibiotics and 16 extend the effectiveness of existing drugs and thereby help combatting the global antibiotic 17 resistance crisis. We describe a computational model (COMBAT-COmputational Model of 18 Bacterial Antibiotic Target-binding) that leverages accessible biochemical parameters to 19 quantitatively predict the antimicrobial effects of antibiotics based on their drug-target affinity. 20
Introduction 31
The rise of antibiotic resistance represents an urgent public health threat. In order to effectively 32 combat the spread of antibiotic resistance, we must optimize the use of existing drugs and 33 develop new drugs that are effective against drug-resistant strains. Accordingly, methods to 34 improve antibiotic dose levels to i) maximize efficacy against susceptible strains and ii) 35 minimize resistance evolution play a key role in our defense against antibiotic resistant 36 pathogens. 37 38 It is noteworthy that dosing strategies for treatment of susceptible strains (e.g., dosing level 1 , 39 dosing frequency 2 , and treatment duration 3-5 ) have recently been substantially improved, even for 40 antibiotic treatments that have been standard of care for decades. This suggests that there likely 41 remains significant room for optimization in our antibiotic treatment regimens. It also highlights 42 the difficulty in identifying optimal dosing levels for new antibiotics. Indeed, optimizing dosing 43 is one of the biggest challenges in drug development. Typically, time-consuming trial-and-error 44 approaches are used and each failed drug candidate makes this process more expensive 6 . 45 46 It is even more challenging to optimize dose levels to minimize the emergence of antibiotic 47 resistance, both for existing and novel antibiotics. There remains substantial debate about which 48 dosing strategies best prevent the emergence of resistant mutants during treatment 7-9 . In this 49 context, a useful concept that links antibiotic concentrations with resistance evolution is the 50 resistance selection window (mutant selection window) that ranges from the lowest 51 concentration at which the resistant strain grows faster than the wild-type, usually well below the 52 wild-type minimum inhibitory concentration (MIC), to the MIC of the resistant strain 10-12 . 53 Antibiotic concentrations above the resistance selection window safeguard against de novo 54 resistance emergence. Antibiotic concentrations below the resistance selection window do not 55 kill the susceptible strain, but also do not favor the resistant strain and therefore do not promote 56 emergence of resistance. The latter may be preferable if one cannot dose above the MIC of the 57 resistant strain due to toxicity or solubility limits. To limit resistance emergence, it is therefore 58 important to identify the resistance selection window and optimize dosing accordingly. 59 60 Limitations in our knowledge of how antibiotic treatment regimens affect bacterial populations 61 contribute to the need for lengthy and expensive trial-and-error approaches, with the sheer 62 number of possible dosing regimens making it difficult to identify an optimal regimen. We argue 63 that this knowledge gap is a major limitation for the improvement of dosing regimens of existing 64 drugs and a real obstacle for the development of new antibiotics 13, 14 . 65 66 Pharmacodynamic models that can make predictions of bacterial killing and selection on the 67 basis of drug-target interactions offer new promise to inform rational antibiotic dosing 68 practices 15 . Recently described models that include drug-target binding have been useful in 69 gaining a better qualitative understanding of complicated drug effects, such as post-antibiotic 70 effects, inoculum effects, and bacterial persistence [15] [16] [17] [18] . However, to speed the development of 71 new antibiotics or to inform practices which minimize resistance, we require quantitative 72 predictions for antibiotics or resistant bacterial strains that do not exist yet. Models which permit 73 quantitative predictions of changes in drug efficacy as a function of modification of antibiotic 74 molecules (i.e. new drugs) or novel resistance mutations would be invaluable. Such tools would 75 advance our general mechanistic understanding of antibiotic action, could guide dosing trials of 76 new drugs, and suggest better dosing of existing drugs. 77
78
In this report, we describe a mechanistic computational modeling framework COmputational Model of Bacterial Antibiotic Target-binding) that allows us to predict drug 80 effects based solely on accessible biochemical parameters describing drug-target interaction. 81
These parameters can be determined early in drug development. We use this framework to 82 investigate how changes in drug target binding, either due to improvements in existing 83 antibiotics or due to resistance mutations in bacteria, affect antibiotic efficacy. We first show that 84 COMBAT accurately predicts bacterial susceptibility as a function of drug-target binding and, 85 conversely, allows inference of these biochemical parameters on the basis of observed patterns of 86 bacterial growth suppression or killing. We then use COMBAT to predict the susceptibility of 87 newly arising resistant variants based on the molecular mechanism of resistance and determine 88 the resistance selection window. 89
90
Results 91
Quinolone target affinities correlate with antibiotic efficacy 92
To investigate how biochemical changes in antibiotic action modifies bacterial susceptibility, we 93 explored how the affinity of antibiotics to their target affects the MIC. We compared the MICs of 94 quinolones, an antibiotic class in which individual antibiotics have a wide range of affinities to 95 their target, gyrase (KD ~10 -4 -10 -7 M) but are of similar molecular sizes and have a similar mode 96 of action 19 . This choice allowed us to isolate the effects of differences in drug-target affinity on 97 the MIC. 98
99
We obtained binding affinities of quinolones to their gyrase target in Escherichia coli from 100 previous studies 20-24 . We then retrieved MIC data for several quinolones from clinical 101 Enterobacteriaceae isolates collected before 1990 25 , i.e., before the widespread emergence of 102 quinolone resistance 19 . We assume that quinolone affinities obtained from clinical 103 Enterobacteriaceae isolates collected before the emergence of resistance correspond to those 104 measured in wild-type E. coli. 105
106
To make qualitative predictions of MICs, we employed a simplified model based on the 107 assumptions that i) drug-target binding occurs much more quickly than bacterial replication, ii) 108 the antibiotic concentration remains constant and iii) that during the 18 hours of an MIC assay, 109 the concentration gradient of the drug inside and outside the cell has equilibrated. Under these 110 assumptions, the MIC can be expressed as 111 While it was encouraging that our model can qualitatively predict MIC changes, our aim was to 123 quantitatively predict antibiotic treatment performance. The simplified model assumes that the 124 binding kinetics are much faster than bacterial replication, which may not be true in all cases. To 125 expand the generalizability of the model, we extended the modeling framework to allow that 126 bacterial replication may occur in a similar time frame as drug-target binding events. 127 128 The full model (COMBAT-COmputational Model of Bacterial Antibiotic Target-binding) 129 describes the binding and unbinding of antibiotics to their targets and predicts how such binding 130 dynamics affects bacterial replication and death (Fig. 2a ). In previous work linking drug-target 131 binding kinetics with bacterial replication 18 , we described a population of bacteria with target 132 molecules per cell with a system of + 1 (bacteria with 0, 1, …, bound target molecules) 133 ordinary differential equations (ODEs). This system increases in complexity with the number of 134 target molecules and makes fitting the model to data computationally too demanding for most 135 settings. To simplify this prior approach, we developed new mathematical models based on 136 partial differential equations (PDEs), where a single equation describes all bacteria 137 simultaneously. The sum of bacteria within all target occupancy states over time can be 138 described by a time kill curve ( Fig. 2b) , during which the bacterial population is characterized by 139 the distribution of bacterial cells with different levels of target occupancies at each time-step 140 ( Fig. 2c ). This curve can be visualized as a two-dimensional surface in a three-dimensional 141 coordinate system where the number of bacteria is represented on the z-axis, the percent of 142 bacteria with the fraction of bound target molecules on the x-axis, and time on the y-axis (Fig. 143 2d). 144 145 Antibiotic action is described by rates of binding (kf) and unbinding (kr) to bacterial target 146 molecules ( Fig. 2a (2) 152
153
The term for binding kinetics is given in brown, the term for replication in blue and the term for 154 death in red. 155 We used the quinolone ciprofloxacin to quantitatively fit bacterial time-kill curves, since this is a 170 commonly used antibiotic for which binding parameters have been directly measured. 171 Supplementary Tab. S1 gives an overview of the known parameters used for fitting; 172 Supplementary Tab. S2 gives the parameters resulting from our fit. 173
174
The functional relationship between the levels of bacterial replication and death on the fraction 175 of bound target molecules is extremely hard to obtain experimentally. We therefore treated the 176 relationships between the fraction of bound target and bacterial replication and death as free 177 parameters in our model fitting. Ciprofloxacin is considered to have both bacteriostatic and 178 bactericidal action (mixed action) 27,28 , and we fitted functions for a monotonically decreasing 179 replication and a monotonically increasing killing with each successively bound target molecule 180 (see Methods & Supplementary Fig. S1 ). 181
182
Overall, we found that COMBAT could fit the time-kill curves well (R 2 = 0.93, Fig. 3a ). Fig. 3b  183 shows the predicted bacterial replication r(x) and death as a function of target occupancy ( ) 184 based on the fit obtained in Fig. 3a . After model calibration, we simulated bacterial replication 185 during exposure to different antibiotic concentrations for 18 h. For this simulation, positive 186 values indicate an increase in the number of bacteria, and negative values indicate a decrease in 187 the number of bacteria. We estimated a MIC of 0.0139 mg/L ( Fig. 3c ), a value that is within the 188 range of MIC determinations for wt E. coli (0.01 mg/L, 0.015 mg/L, 0.017 mg/L and 0.023 mg/L 189 11,29-31 ). 190
Accurate prediction of target overexpression from time-kill data 191
Having shown that COMBAT can quantitatively fit experimental data on antibiotic action within 192 biologically plausible parameters, we continued to test the predictive ability of the model. Given 193 our hypothesis that modifications in antibiotic-target interactions lead to predictable changes in 194 bacterial susceptibility, we experimentally induced changes in the antibiotic-target interaction of 195 ciprofloxacin in E. coli. We then quantified these biochemical changes by fitting COMBAT to 196 corresponding time-kill curves and compared them to the experimental results. Ciprofloxacin 197 acts on gyrase A2B2 tetramers 19 . We used an E. coli strain for which both gyrase A and gyrase B 198 are under the control of a single inducible promoter (PlacZ), such that the amount of gyrase A2B2 199 tetramer can be experimentally manipulated 32 . We measured net growth rates for this strain at 200 different ciprofloxacin concentrations in the presence of 10 µM isopropyl β-D-1-201 thiogalactopyranoside (IPTG; mild overexpression) and 100 µM IPTG (strong overexpression) 202 and compared it to the wild-type in the absence of the inducer (Fig. 4a ). 203
204
Like previously reported, we find that increasing gyrase content makes E. coli more susceptible 205 to ciprofloxacin 32 . We fitted net growth rates allowing the target molecule content, i.e. gyrase 206 A2B2, to vary. We assumed that the only change between the different conditions was the amount 207 of target. We further assumed that the relationship between bound target and bacterial replication 208 or death did not differ between the control strain containing a mock plasmid (no IPTG) and the 209 experiments with overexpression ( Fig. 4b , between 0 % and 100 %). Finally, we assumed that 210 the maximal kill rate at very high antibiotic concentrations was accurately measured in our 211 experiments and forced the function describing bacterial death through the measured value when 212 all target molecules are bound. We found the best fit for a 1.31x increase in GyrA2B2 target 213 molecule content for bacteria grown in the presence of 10 µM IPTG and a 2.02x increase in 214
GyrA2B2 target molecule content for those grown in the presence of 100 µM IPTG. 215
We subsequently tested these predictions experimentally by analyzing Gyrase A and B content 217 by western blot Fig. 4c ; Supplementary Fig. S2 ). Using realistic association and dissociation 218 rates for biological complexes 33 , we predicted a range of functional tetramers based on the 219 relative amount of Gyrase A and B proteins ( Fig. 4d ). Supplementary Tab. S3 details the 220 individual measurements, and the procedure to estimate tetramers is provided in the methods 221 section. We found that the observed overexpression was very close to our theoretical prediction, Next, we tested whether COMBAT can be applied to the action of the beta-lactam ampicillin, a 228 very different antibiotic with a distinct mode of action from quinolones. Using published 229 pharmacodynamic data of E. coli exposed to ampicillin 31 also allowed us to compare COMBAT 230 predictions to established pharmacodynamic approaches. Most of the biochemical parameters for 231 ampicillin binding to its target, penicillin-binding proteins (PBPs), have been determined 232 experimentally (Supplementary Tab. S1). Ampicillin is believed to act as a bactericidal drug 34 , 233 and this mode of action is supported by findings from single-cell microscopy 26 . We therefore 234 assume that ampicillin binding does not affect bacterial replication. In order to model the 235 consumption of beta-lactams at target inhibition and eventual target recovery, we made small 236 adjustments to equation 13 (see Methods, description of beta-lactam action). 237
238
We fitted COMBAT to published time-kill curves of E. coli exposed to ampicillin ( Fig. 5a ). 239
Again, COMBAT provides a good fit to the experimental data between 0 min and 40-60 min. 240
After that time, observed bacterial killing showed a characteristic slowdown at high ampicillin 241
concentrations which is often attributed to persistence 18 (Fig. 5a ). For the sake of simplicity, we 242 chose to omit bacterial population heterogeneity in this work and therefore cannot describe 243 persistence, even though COMBAT can be adapted to capture this phenomenon 18 . Because 244 ampicillin acts in an entirely bactericidal manner, we assume a constant replication rate (see 245
Methods & Supplementary Fig. S1 ) and fitted bacterial death as a function of target binding, 246 ( ) ( Fig. 5b , fitted parameters in Tab. S4). Having established that COMBAT can also adequately capture the pharmacodynamics of 254 ampicillin, we next tested whether we can estimate experimentally determined target occupancy 255 at the MIC. Our estimated mean occupancy considering both living and dead bacteria is 89 % 256 ( Fig. 5b) , a value within previously reported experimental estimates from Staphylococcus aureus 257 (84-99 %) 35 . 258 259
Sensitivity of antibiotic efficacy to parameters of drug-target binding 260
It is possible to vary all parameters in COMBAT and explore their effect. We used this to test 261 how hypothetical chemical changes to ampicillin or ciprofloxacin would affect antibiotic 262 efficacy ( Supplementary Fig. S3 -S11). These changes could reflect either bacterial resistance 263 mutations or modifications of the antibiotics themselves. We predict that changes in drug-target 264 affinity, KD, have more profound effects than changes in target molecule content, bacterial 265 reaction to increasingly bound target (i.e. d(x) and r(x)), or changes in target molecule content.
266
We also predict that the individual binding rates kr and kf, and not just the ratio of these terms, 267
the KD, are important factors in efficiency. The faster a drug binds, the more efficient we 268 predicted it will be. One intuitive explanation for the observation that kf drives efficacy is that a 269 slow binding fails to rapidly interfere with bacterial replication, which may allow for the 270 production of additional target molecules and thereby reduce the ratio of free antibiotic to target 271 molecules. 272 273
Forecasting the resistance selection window 274
Finally, we illustrate how COMBAT can be used to explore how the molecular mechanisms of 275 resistance mutations affect antibiotic concentrations at which resistance can emerge, i.e., the 276 resistance selection window. We compared predicted net growth rates as a function of 277 ciprofloxacin concentrations for a wild-type strain and an archetypal resistant strain. For this 278 analysis, we assumed that the resistant strain has a 100x slower drug-target binding rate (i.e. 279 ~100x increased MIC, realistic for novel point mutations 36 ) and that the maximum replication 280 rate of the resistant strain is 85 % of the wild type strain 37 . We then predicted the antibiotic 281 concentrations at which resistance would be selected. Interestingly, when comparing COMBAT 282 to previous pharmacodynamics models ( Fig. 5 ), we observed that estimates of replication rates 283 depend on the selected time frame (Fig. 6a ). When the timeframe for MIC determination is set to 284 18 h as defined by CLSI 38 , the "competitive resistance selection window", i.e., the concentration 285 range below the MIC of both strains where the resistant strain is fitter than the wild type, ranges 286 from 0.002 mg/L to 0.014 mg/L for ciprofloxacin ( Fig. 6a ) and 1 mg/L to 2.6 mg/L for 287 ampicillin ( Supplementary Fig. S12 ), respectively. This corresponds well with previous 288 observations that ciprofloxacin resistance is selected for well below MIC 11 . However, when 289 measuring after 15 min or 45 min, the results are substantially different. The reason for this is 290 illustrated in Fig. 6b . COMBAT reproduces non-linear time kill curves where bacterial 291 replication continues until sufficient target is bound to result in a negative net growth rate. This 292 compares well with experimental data around MIC in Fig. 3a and 5a . In Fig. 6b MICResistant; 18 h). In all cases, the bacterial population first increases and then decreases slowly. 296
This may have consequences for the selection of resistant strains. Fig. 6c illustrates how the 297 resistance selection windows depending on the observed time frame. This suggests that even at 298 concentrations above the 18 h MIC of the resistant strain, there may be initial growth of the 299 resistant strain. In this case, the resistant strain could continue growing at concentration of up to 300 7 mg/L ciprofloxacin at 15 min, even though the MIC at 18 h is 1.27 mg/L. 301 302 Discussion 303
Optimizing dosing levels of antibiotics is important for maximizing drug efficacy against wild-304 type strains as well as for minimizing the rise of resistant mutants. The determination of optimal 305 dosing strategies typically requires expensive empirical studies; the need for such studies arises 306 in part from our currently limited capacity to predict how antibiotics will affect bacteria at a 307 given concentration. In fact, drug attrition is mainly due to insufficient predictions of efficacy 308 (pharmacodynamics) rather than pharmacokinetics 6 . For optimizing drug development and for 309 minimizing resistance, we need quantitative predictions for antibiotics or resistant bacterial 310 strains that do not exist yet. The ability to accurately predict MICs on the basis of biochemical 311 parameters and, more generally, to define antibacterial activity across a range of drug 312 concentrations, would allow us to estimate antibiotic efficacy for novel compounds or against not 313 yet emerged resistant strains 15, 39 . Recent studies have reported methods to predict MICs from 314 whole genome sequencing data 40,41 . However, these methods require transfer of prior knowledge 315 on how the resistance mutations affect MICs in other organisms. There are no methods that could 316 predict a priori how chemical changes to an antibiotic structure or novel resistance mutations 317 affect bacterial growth at a given antibiotic concentration. 318 319 Here, we accurately predict antibiotic action on the basis of accessible biochemical parameters of 320 drug-target interaction. Our computational model, COMBAT provides a framework to predict 321 the efficacy of compounds based on drug-target affinity, target number, and target occupancy. 322
These parameters may change both when improving antibiotic lead structures as well as when 323 bacteria evolve resistance. Importantly, they can be measured early in drug development and 324 may even be a by-product of target-based drug discovery 42 . When these data are available, 325 COMBAT makes only one assumption: that the rate of bacterial replication decreases and/or the 326 rate of killing increases with successive target binding. While fitting, we allow this relationship 327 to be gradual or abrupt and select the best fit. This means we do not model specific molecular 328 mechanisms down-stream of drug-target binding, but their effects are subsumed in the functions 329 that connect the kinetic of drug-target binding to bacterial replication and death. 330
331
In previous work, for example on antipsychotics 16 , antivirals 17 and antibiotics 15,18 , models of 332 drug-target binding kinetics have been used to improve our qualitative understanding of 333 pharmacodynamics. Our study substantially advances this work by making accurate quantitative 334 predictions across antibiotics and bacterial strains when measurable biochemical characteristics 335 change. This is possible because COMBAT employs an elegant mathematical approach, based 336 on partial differential equations, that makes it computationally feasible to fit the model to a large 337 range of data. Importantly, we are not only able to predict antibiotic action from biochemical 338 parameters, but can also vice versa use COMBAT to accurately predict biochemical changes 339 from observed patterns of antibiotic action. We have confirmed the excellent predictive power of 340 COMBAT with clinical data as well as experiments with antibiotics with very different 341 mechanisms of action. This gives us confidence that biochemical parameters are major 342 determinants of antibiotic action in bacteria and that COMBAT helps to make rational decisions 343 about antibiotic dosing. 344
345
In drug development, our mechanistic modeling approach provides insight into which chemical 346 characteristics of drugs may be useful targets for modification. For example, our sensitivity 347 analyses indicate that antibiotics with a similar affinity but faster binding inactivate bacteria 348 more quickly and therefore prevent replication and production of more target molecules, which 349 would change the ratio of antibiotic to target. Furthermore, because e.g. antibiotic binding and Our approach also offers insight into determinants of the resistance selection window. Rather 365 than determining the resistance selection window for a comprehensive collection of possibly 366 arising resistance mutations in each bacteria-drug pair, it would be attractive to build 367 transferrable knowledge that allows estimating the resistance selection window. In concordance 368 with a recent meta-analysis of experimental data 43 , our sensitivity analyses predict that changes 369 in drug target binding and unbinding have a greater impact on the MIC than changes in target 370 molecule content or down-stream processes. Thus, a more comprehensive characterization of the 371 binding parameters of spontaneous resistant mutants would allow an overview of the maximal 372 biologically plausible levels of resistance that can arise with one mutation. Dosing above this 373 level should then safeguard against resistance. This is especially useful for compounds for which 374 it is difficult to saturate the mutational target for resistance, or for safeguarding against resistance 375 to newly introduced antibiotics for which we do not yet have a good overview of resistance 376 conferring mutations. If toxicity, solubility or other constraints do not allow dosing above the 377 MIC of expected resistant strains, COMBAT can predict the concentration range at which 378 resistance is less strongly selected. This could guide decisions on treating with low versus high 379 doses, which is currently controversially debated 7,8 . Good quantitative estimates on the dose-380 response relationship of new drugs would also help defining the therapeutic window, i.e. the 381 range of drug concentrations at which the drug is effective but not yet toxic. In the most basic version of COMBAT, we ignored differences between extracellular and 402 intracellular antibiotic concentrations and only followed the total antibiotic concentration A, 403 assuming that the time needed for drug molecules to enter bacterial cells is negligible. We model 404 ciprofloxacin (to which there is a limited diffusion barrier 46 ) and ampicillin (where the target is 405 not in the cytosol, even though the external membrane in gram negatives has to be crossed to 406 reach PBPs). We therefore believe that this assumption is justified in wild-type E. coli. This 407 basic version of COMBAT is therefore more accurate for describing antibiotic action where the 408 diffusion barrier to the target is weak. 409 410
Binding kinetics 411
We describe the action of antibiotics as a binding and unbinding process to bacterial target 412 molecules 18 . For simplicity, we assume a constant number of available target molecules . The 413 binding process is defined by the formula + ⇌ , where the intracellular antibiotic 414 molecules A react with target molecules T at a rate k f and form an antibiotic-target molecule 415 complex x, where values for x range between 0 and . If the reaction is reversible, the complex 416 dissociates with a rate k r . 417
In 18 , the association and dissociation terms are described by the following terms 418 , kf is the association rate, Vtot is the volume in which the experiment is 422 performed, nA is Avogadro's number, kr is the dissociation rate, Bi is the number of bacteria with 423 i bound targets, and is the total number of targets. Green denotes the association term, while 424 the dissociation term is in orange. 425
This approach requires the use of a large number of ordinary differential equations, ( + 1) for 426 the bacterial population and one for the antibiotic concentration. To generalize this approach, we 427 assume that the variable of bound targets is a real number ∈ ℛ. Under this continuity 428 assumption, we consider the bacterial cells as a function of x and the time t, thereby reducing the 429 total number of equations to two. 430
Under the continuity approximation ( ∈ ℛ), we can rewrite the binding kinetics in the form 431 
Replication rate 441
We assume that the replication rate of bacteria, r(x), is dependent on the number of bound target 442 molecules x. The function r(x) is a monotonically decreasing function of x, such that fewer 443 bacteria replicate as more target is bound. r(0) is the maximum replication rate, corresponding to 444 the replication rate of bacteria in absence of antibiotics. Thus, r(x) describes the bacteriostatic 445 action of the antibiotics, i.e., the effect of the antibiotic on bacterial replication. 
Distribution of target molecules upon division 456
We assume that the total number of target molecules doubles at replication, such that each 457 daughter cell has the same number as the mother cell. We also assume that the total number of 458 drug-target complexes is preserved in the replication and that the distribution of x bound target 459 molecules of the mother cell to its progeny is described by a hypergeometric sampling of n 460 molecules from x bound and 2 − unbound molecules. Under the continuity assumption, we 461 generalize the concept of hypergeometric distribution. Because the hypergeometric distribution 462 is a function of combinations and because a combination is defined as function of factorials, we 463 can use functions in place of factorials and redefine a continuous hypergeometric distribution 464 as a function of functions. A function is 465
where is a complex number. In this way, the distribution can be expressed as a probability 468 density function of continuous variables. The amount of newborn bacteria is given by the term 469 ( ) ( , ) H<I ( ). We assume that bound target molecules are distributed randomly between 470 mother and daughter cells, with each of them inheriting 50% upon division on average. This 471 means that twice the amount of newborn cells must be redistributed along x to account for the 472 random distribution process. For example, if a mother cell with 4 bound targets divides, we have 473 two daughter cells, each with a number of bound targets between 0 and 4 (their sum has to be 4), 474
following the generalized hypergeometric distribution. For simplicity, we define S(x,t) to be a 475 function related to the replication rate that depends on the number of bacteria with a number of 476 bound target molecules ranging between x and , their specific replication rate r( We consider several potential functional forms of the relationship between the percentage of 488 bound targets and replication and death rates, because the exact mechanisms how target 489 occupancy affects bacteria is unknown ( Supplementary Fig. S1 ). We use a sigmoidal function 490 that can cover cases ranging from a linear relationship to a step function. When the inflection 491 point of a sigmoidal function is at 0 % or 100 % target occupancy, the relationship can also be 492 described by an exponential function. We assume that replication in bactericidal and death in 493 At t = 0, we assume that all bacteria have zero bound targets ( = 0), and the initial 529 concentration of bacteria is ( , 0) = 0, > 0, and (0,0) = Y . 530
At the boundaries of the partial differential equation ( = 0, = ), we specify that the outgoing 531 velocities are zero. For = 0, i.e. no bound target molecules, the unbinding velocity Z (0, ) = 532 0, and in = , i.e. all targets are bound, the binding velocity ' ( , ) = 0. When the 533 replication term at = 0 and the death term at = are known, we can solve the partial 534 differential equation with two ordinary differential equations at the boundaries. They are similar 535 to the equations at = 0 and at = described by Abel zur Wiesch et al. 18 verified that the Courant-Friedrichs-Lewy condition is satisfied. For fitting the experimental data 544 of bacteria exposed to ciprofloxacin and ampicillin, we used the particle swarm method 545 ("particleswarm" function in Matlab, MathWorks software). 546 547
Concentrations of gyrase A2B2 tetramers 548
We assumed that gyrases A and B first homo-dimerize to A2 and B2, respectively, which in turn 549 bind to each other to form the tetramer TR 48 . approach from a biologically plausible range where the association rates are between 10 7 -10 9 559 M -1 s -1 and the dissociation rates between 10 -3 -10 -1 s -1 33 . This results in 10 4 estimates for each of 560 the six experimental replicates quantifying gyrase A and B (Fig. 4, Supplementary Fig. S2 (2.187 mg/L) were used to determine the minimal and maximal kill rate, respectively. Samples 581 were taken immediately prior to addition of the antibiotic and in ~20 min intervals or after 45 582 min, respectively. Samples were washed once in phosphate buffered saline (PBS) before colony 583 forming units (CFUs) were determined for each sample by plating a 1:10 dilution series in PBS 584 on LB agar plates. 585 586
GyrAB quantification 587
Band intensities were quantified from unmodified images using the record measurement tool of 611 Photoshop CS6, normalized to the CRP loading control after background subtraction, and 612 reported relative to SoA3330. For clarity, the "levels" tool of Photoshop CS6 was used to 613 enhance the contrast of shown Western blot images. 614 615
Data Availability 616
Computer code will be available at https://www.abel-zur-wiesch-lab.com/. 617 618
Fig. 1| Clinical data confirm linear correlation between MICs and affinities of quinolones to 637
gyrase. We analyzed MIC and drug-target affinity data from 11 Enterobacteriaceae isolates and 638 seven different quinolones. The x-axes show the affinities (KD), and the y-axes show the MICs, 639 both in mol/L. The adjusted R 2 and p-value of each correlation are given. In cases where there 640 was more than one KD value reported in the literature, we used the mean for this analysis. The 641
tested MIC values are the median of several clinical isolates described previously 25 . 642 targets predicted by the model fit in (a). The black line indicates the predicted distribution of 695 target occupancies in a bacterial population (both living and dead cells) exposed to ampicillin at 696 the MIC for 18 h. c, The net growth rate, as determined by the slope of a line connecting the 697 initial bacterial density and the bacterial density at 18 h on a logarithmic scale predicted from the 698 model fit in (a), is shown as function of the drug concentration (blue). The dotted horizontal line 699 indicates zero net growth, and the intersection with the blue line predicts the MIC (2.6 mg/mL). 700 
